Display options
Cite
Lal A, Jaoude P, El-Solh AA. Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother. 2016;48(2):81-90doi: 10.3947/ic.2016.48.2.81.
Lal, A., Jaoude, P., & El-Solh, A. A. (2016). Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infection & chemotherapy, 48(2), 81-90. https://doi.org/10.3947/ic.2016.48.2.81
Lal, Ashima, et al. "Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis." Infection & chemotherapy vol. 48,2 (2016): 81-90. doi: https://doi.org/10.3947/ic.2016.48.2.81
Lal A, Jaoude P, El-Solh AA. Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother. 2016 Jun;48(2):81-90. doi: 10.3947/ic.2016.48.2.81. Epub 2016 Jun 30. PMID: 27433378; PMCID: PMC4945731.
Copy Download .nbib Format: NLM
Share it on

Infect Chemother. 2016 Jun;48(2):81-90. doi: 10.3947/ic.2016.48.2.81. Epub 2016 Jun 30.

Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.

Infection & chemotherapy

Ashima Lal, Philippe Jaoude, Ali A El-Solh

Affiliations

  1. The Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA.; Western New York Respiratory Research Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine and Department of Social and Preventive Medicine, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
  2. The Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA.; Western New York Respiratory Research Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine and Department of Social and Preventive Medicine, State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA.; School of Public Health and Health Professions, Buffalo, NY, USA.

PMID: 27433378 PMCID: PMC4945731 DOI: 10.3947/ic.2016.48.2.81

Abstract

BACKGROUND: The primary objective of this meta-analysis is aimed at determining whether β-lactams prolonged infusion in patients with nosocomial pneumonia (NP) results in higher cure rate and improved mortality compared to intermittent infusion.

MATERIALS AND METHODS: Relevant studies were identified from searches of MEDLINE, EMBASE, and CENTRAL from inception to September 1st, 2015. All published articles which evaluated the outcome of extended/continuous infusion of antimicrobial therapy versus intermittent infusion therapy in the treatment of NP were reviewed.

RESULTS: A total of ten studies were included in the analysis involving 1,051 cases of NP. Prolonged infusion of β-lactams was associated with higher clinical cure rate (OR 2.45, 95% CI, 1.12, 5.37) compared to intermittent infusion. However, there was no significant difference in mortality (OR 0.85, 95% CI 0.63-1.15) between the two groups. Subgroup analysis for β-lactam subclasses and for severity of illness showed comparable outcomes.

CONCLUSION: The limited data available suggest that reduced clinical failure rates when using prolonged infusions of β-lactam antibiotics in critically ill patients with NP. More detailed studies are needed to determine the impact of such strategy on mortality in this patient population.

Keywords: Clinical cure; Mortality; Prolonged infusion; β-lactams

References

  1. Clin Ther. 2007 Nov;29(11):2433-9 - PubMed
  2. Int J Antimicrob Agents. 2009 May;33(5):464-8 - PubMed
  3. Antimicrob Agents Chemother. 2005 Apr;49(4):1337-9 - PubMed
  4. Med Intensiva. 2009 Dec;33(9):442-9 - PubMed
  5. Clin Infect Dis. 2013 Jan;56(2):272-82 - PubMed
  6. Pharmacotherapy. 2002 May;22(5):569-77 - PubMed
  7. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008481 - PubMed
  8. Crit Care. 2012 Jun 28;16(3):R113 - PubMed
  9. Crit Care Med. 2005 Oct;33(10):2184-93 - PubMed
  10. Health Technol Assess. 2003;7(27):iii-x, 1-173 - PubMed
  11. Pharmacotherapy. 2006 Sep;26(9):1320-32 - PubMed
  12. Intensive Care Med. 2004 May;30(5):989-91 - PubMed
  13. Ann Pharmacother. 2012 Feb;46(2):265-75 - PubMed
  14. Crit Care Med. 2008 May;36(5):1500-6 - PubMed
  15. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2 - PubMed
  16. Pharmacotherapy. 2002 Apr;22(4):471-83 - PubMed
  17. Clin Infect Dis. 2007 Feb 1;44(3):357-63 - PubMed
  18. J Antimicrob Chemother. 2001 Aug;48(2):259-67 - PubMed
  19. Indian J Crit Care Med. 2012 Jul;16(3):141-7 - PubMed
  20. N Engl J Med. 1946 Nov 14;235(20):699-706 - PubMed
  21. J Antimicrob Chemother. 2008 Feb;61(2):382-8 - PubMed
  22. Int J Antimicrob Agents. 2014 May;43(5):403-11 - PubMed
  23. J Intensive Care Med. 2006 Jul-Aug;21(4):211-26 - PubMed
  24. Am J Surg. 2000 Jun;179(6):436-40 - PubMed
  25. Control Clin Trials. 1996 Feb;17(1):1-12 - PubMed
  26. Crit Care Med. 2008 Apr;36(4):1089-96 - PubMed
  27. Crit Care. 2013 Nov 29;17(6):R279 - PubMed
  28. Lancet Infect Dis. 2005 Sep;5(9):581-9 - PubMed
  29. Ann Pharmacother. 2006 Feb;40(2):219-23 - PubMed
  30. Clin Ther. 2002 Jul;24(7):1090-104 - PubMed
  31. Am J Med. 1993 Mar;94(3):281-8 - PubMed
  32. BMC Infect Dis. 2011 Jun 22;11:181 - PubMed
  33. J Antimicrob Chemother. 2007 Feb;59(2):285-91 - PubMed
  34. Int J Antimicrob Agents. 2009 Mar;33(3):290-1 - PubMed
  35. Crit Care Med. 2009 Jun;37(6):2071-8 - PubMed
  36. Lancet Infect Dis. 2013 Aug;13(8):665-71 - PubMed
  37. Antimicrob Agents Chemother. 2007 Sep;51(9):3304-10 - PubMed
  38. Antimicrob Agents Chemother. 2013 Dec;57(12):5811-9 - PubMed
  39. Int J Clin Pharmacol Ther. 2005 Aug;43(8):360-9 - PubMed
  40. Pharmacotherapy. 2001 May;21(5):549-55 - PubMed

Publication Types

Grant support